Table 2.
Concomitant Medications at Baseline
| Medication Class | All (N = 40) | Placebo (n = 13) | Cimaglermin |
|
|---|---|---|---|---|
| Low Dose (n = 12) | High Dose (n = 15) | |||
| Beta-blocker | 39 (98) | 12 (92) | 12 (100) | 15 (100) |
| ACEI or ARB | 32 (80) | 10 (77) | 11 (92) | 11 (73) |
| Diuretic | 35 (88) | 10 (77) | 11 (92) | 14 (93) |
| MRA | 27 (68) | 5 (38) | 8 (67) | 14 (93) |
| Statin or other cholesterol-lowering | 34 (85) | 11 (85) | 10 (83) | 13 (87) |
| Aspirin | 28 (70) | 10 (77) | 10 (83) | 8 (53) |
| Other antiplatelet | 16 (40) | 4 (31) | 4 (33) | 8 (53) |
| Anticoagulant | 14 (35) | 6 (46) | 4 (33) | 4 (27) |
| Antiarrhythmic | 10 (25) | 5 (38) | 2 (17) | 3 (20) |
| Digoxin | 18 (45) | 5 (38) | 9 (75) | 4 (27) |
| Vasodilator | 34 (85) | 11 (85) | 10 (83) | 13 (87) |
Values are n (%). Patients previously on strong CYP3A/4 inhibitors had dose adjustments 2 weeks prior to receiving study drug, as cimaglermin was observed to affect CYP3A4 activity in vitro, which is being explored clinically.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; MRA = mineralocorticoid receptor antagonist.